Padilla Monica Angelica Amaya, Binju Mudra, Wan Graeme, Rahmanto Yohan Suryo, Kaur Pritinder, Yu Yu
School of Pharmacy & Biomedical Science, Curtin University, Curtin Health Innovative Research Institute, Perth, WA 6102, Australia.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.
Cancer Drug Resist. 2019 Dec 19;2(4):1127-1135. doi: 10.20517/cdr.2019.76. eCollection 2019.
Investigating the biological processes that occur to enable recurrence and the development of chemoresistance in ovarian cancer is critical to the research and development of improved treatment options for patients. The lethality of ovarian cancer is largely attributed to the recurrence of disease with acquired chemoresistance. Cancer stem cells are likely to be critical in ovarian cancer progression, contributing to tumour malignancy, metastasis and recurrence by persisting in the body despite treatment with anti-cancer drugs. Moreover, cancer stem cells are capable of mediating epithelial-to-mesenchymal transition traits and secrete extracellular vesicles to acquire therapy resistance and disease dissemination. These attributes merit in depth research to provide insight into the biological role of ovarian cancer stem cells in disease progression and chemotherapy response, leading to the development of improved biomarkers and innovative therapeutic approaches.
研究卵巢癌复发及产生化疗耐药性所涉及的生物学过程，对于为患者研发更好的治疗方案至关重要。卵巢癌的致死率很大程度上归因于疾病复发及获得性化疗耐药。癌症干细胞可能在卵巢癌进展中起关键作用，通过在接受抗癌药物治疗后仍存于体内，导致肿瘤恶性化、转移和复发。此外，癌症干细胞能够介导上皮-间质转化特征并分泌细胞外囊泡以获得治疗抗性和疾病传播能力。这些特性值得深入研究，以深入了解卵巢癌干细胞在疾病进展和化疗反应中的生物学作用，从而开发出更好的生物标志物和创新治疗方法。
